Dutasteride may be considered as cure option for men who are at elevated risk for prostate cancer.. Gerald L. Andriole, M.D., David G. Bostwick, M.D., Otis W. Brawley, M.D., Leonard G. Gomella, M.D., Michael Marberger, M.D., Francesco Montorsi, M.D., Curtis A. Pettaway, M.D., Teuvo L. Tammela, M.D., Claudio Teloken, M.D., Ph.D., Donald J. Tindall, Ph.D., Matthew C. Somerville, M.S., Timothy H. Wilson, M.S., Ivy L. Fowler, B.S.N., and Roger S. Rittmaster, M.D.1 The total results of the Prostate Cancer tumor Prevention Trial showed that finasteride, in comparison with placebo, decreased the risk of prostate cancer by 25 percent, but among the tumors that were detected, there is a 27 percent increase in the number of those that acquired Gleason scores of 7 to 10.2 A subsequent evaluation showed that the odds ratio for tumors with Gleason ratings of 7 to 10 in the finasteride group reduced from 1.27 to 1 1.03 in a logistic model that included both baseline variables that are known to have an effect on the risk of cancer and the post-baseline prostate volume.This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an editorially independent information service, is a scheduled program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
AMP assured in lawsuit to invalidate patents on two breast cancer genes Now that the Supreme Courtroom offers remanded Association for Molecular Pathology et al. V. Myriad Genetics, Inc., et al. to the Courtroom of Appeals for the Federal government Circuit for further thought, AMP can be optimistic that it will ultimately prevail in its lawsuit to invalidate patents on two genes that are recognized to cause breast tumor.